Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.990
-0.010 (-0.33%)
Nov 5, 2024, 4:00 PM EST - Market closed
Allogene Therapeutics Employees
As of December 31, 2023, Allogene Therapeutics had 233 total employees, including 232 full-time and 1 part-time employees. The number of employees decreased by 128 or -35.46% compared to the previous year.
Employees
233
Change (1Y)
-128
Growth (1Y)
-35.46%
Revenue / Employee
$279
Profits / Employee
-$1,199,240
Market Cap
625.24M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Community Health Systems | 61,000 |
Pharming Group | 382 |
SI-BONE | 344 |
Simulations Plus | 197 |
Acelyrin | 135 |
Terns Pharmaceuticals | 66 |
Q32 Bio | 37 |
Third Harmonic Bio | 30 |
ALLO News
- 11 hours ago - Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 6 days ago - Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity - GuruFocus
- 5 weeks ago - Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference - GlobeNewsWire
- 2 months ago - Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies - Seeking Alpha
- 3 months ago - Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewsWire